Osimertinib is the preferred first-line treatment in patients with EGFR-mutated advanced non–small-cell lung cancer. Whether adding chemotherapy to osimertinib could improve outcomes is unclear.

New research findings are summarized in a short video.

To see the full article, follow this link: https://nej.md/3Sg4Tqy